BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Jun 29, 2009
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Ipilimumab: Preliminary Phase II data

Preliminary data from an open-label Phase II trial showed that 2 patients whose prostate cancer had previously been considered inoperable were cancer free after treatment with ipilumumab plus androgen ablation hormone...

Read the full 133 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >